SELLAS Life Sciences Group, Inc. — Filing Summary
Entity and period: The supplied filing is RXi Pharmaceuticals Corporation’s unaudited Form 10-Q for the quarter ended June 30, 2011, not a filing under the name SELLAS Life Sciences Group, Inc. The company was a development-stage biotechnology business; its principal candidate included NeuVax (E75).
Financial performance and position
| Metric | Q2 2011 / June 30, 2011 | Comparison |
|---|---|---|
| Revenue | None reported; the company said it had generated no revenue since inception. | No product revenue expected in the foreseeable future. |
| Operating loss | $4.622 million for Q2; $9.901 million for the first half. | Q2 2010: $4.754 million; first half 2010: $9.210 million. |
| Net loss | $1.382 million for Q2; $5.227 million for the first half. | Q2 2010: $2.141 million; first half 2010: $6.027 million. |
| Loss per share | $0.04 Q2; $0.18 first half. | $0.12 and $0.35, respectively, in 2010. |
| Cash and cash equivalents | $17.933 million. | $6.891 million at December 31, 2010; $5.093 million at June 30, 2010. |
| Cash flow, first half | Operations used $7.086 million; investing provided $0.115 million; financing provided $18.013 million. | Operating cash use was $6.151 million in first-half 2010. |
| Liquidity and liabilities | Current assets $18.192 million; current liabilities $16.819 million; total liabilities $22.493 million. | Cash runway management estimated through at least Q2 2012. |
Research and development expense was $2.673 million in Q2 and $4.833 million in the first half, up 18% and 15%, respectively. Management attributed the increases mainly to NeuVax-related consulting and development activity. General and administrative expense was $1.949 million in Q2 and $5.068 million in the first half; first-half expense increased 1% year over year.
Margins are not meaningful because the company reported no revenue. Capital-lease obligations totaled approximately $69,000. More significant recorded obligations included $11.882 million of warrants potentially settleable in cash and $6.432 million of contingent Apthera purchase consideration. The filing reports no conventional material borrowing balance beyond capital leases.
Changes, transactions, and unusual items
- Net loss was lower than the comparable periods, despite higher first-half operating loss, partly because of non-cash gains from changes in warrant fair values and grant income. Other income was $3.243 million in Q2 and $4.678 million in the first half; the first-half amount included $4.493 million of non-cash warrant-related income and $186,000 in government grants. These gains do not represent operating revenue or cash generation.
- RXi acquired Apthera on April 13, 2011, issuing approximately 5.0 million shares and agreeing to contingent payments of up to $32 million tied to NeuVax milestones. The estimated acquisition consideration was $12.827 million, including $6.460 million of estimated earn-out value; the purchase-price allocation was preliminary.
- March and April 2011 public offerings generated approximately $18.060 million in net proceeds during the first half. The April offering included warrants; the company recorded $11.882 million of potentially cash-settleable warrant liabilities at quarter-end. The associated fair-value accounting materially affected reported earnings.
- Outstanding options and warrants were substantial: 5.6 million options and 20.2 million warrants at June 30, 2011. Potential shares were excluded from diluted loss per share as anti-dilutive.
- The company reported no legal proceedings, defaults on senior securities, or material changes to internal control over financial reporting. Management said disclosure controls were effective.
Outlook, risks, and contingencies
Management expected expenses to rise as it advanced NeuVax and incorporated Apthera, and said existing cash should fund operations through at least the second quarter of 2012. RXi expected to require additional third-party funding, potentially through equity, research funding, or partnerships; it cautioned that funding might not be available on acceptable terms or at all, potentially forcing it to reduce or terminate operations or pursue a merger or acquisition.
NeuVax was expected to enter a Phase 3 trial in the first half of 2012 for adjuvant treatment of early-stage HER2 breast cancer, subject to satisfying FDA information requirements and release from a partial clinical hold. The company also said it was assessing strategic options for its RNAi platform. The MD Anderson/Henry M. Jackson Foundation license carried annual maintenance fees of $175,000 in 2011 and $200,000 in 2012, plus a $200,000 milestone payment upon Phase 3 commencement and potential royalties. Stockholders approved an increase in authorized common shares to 125 million on July 15, 2011, after quarter-end.
Important facts for investors to verify
- Confirm the filing identity: the source is RXi Pharmaceuticals Corporation’s 2011 Form 10-Q, despite the SELLAS company label in the request.
- Track cash burn and financing needs against management’s runway estimate through Q2 2012; the estimate depends on spending and access to future capital.
- Verify NeuVax’s FDA clinical-hold status and actual timing and conditions for the proposed Phase 3 trial.
- Assess dilution and potential cash obligations from the large warrant and option overhang, as well as the Apthera milestone consideration.
- Distinguish operating performance from reported net loss: warrant fair-value gains reduced losses but were largely non-cash, while the company had no product revenue.